Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023 - Seite 2
_____________________________________
1 SkyQuest Large Molecule Industry Forecast, February 2024
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated CDMO focused on manufacturing biologic and cell therapy programs for our clients. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
Lesen Sie auch
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as
the bookings, coupled with the strong interest in the Company’s microbial and mammalian capabilities and promising pipeline of new opportunities, positions it well for significant growth in 2024
and beyond; the large molecule drug substance CDMO market projected growth from $10 billion in 2023 to $21 billion by 2030; being well-positioned to capture a meaningful share of the market;
Scorpius’ growth accelerating in 2024 and becoming cash flow positive by early 2025; the future for Scorpius could not be brighter as its 60,000+ sq. ft. campus provides it sufficient capacity to
grow its business with minimal additional capex requirements, and maximizing profits and returns for its shareholders. Important factors that could cause actual results to differ materially from
current expectations include, among others, the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its bookings and continue to grow
revenue; the ability to capture a meaningful market share; he ability to become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its
ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with
ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the
Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new
information, future events, or otherwise, except as required by law.